MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature

Tuberculosis (TB) is accountable for considerable global morbidity and mortality. Effective TB therapy with multiple drugs completes in about six months. The longer duration of TB therapy challenges patient compliance and contributes to treatment collapse and drug resistance (DR) progress. Therefore...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Mohd. Imran, Mandeep Kumar Arora, Anurag Chaudhary, Shah Alam Khan, Mehnaz Kamal, Manal Mutlaq Alshammari, Raghad Mohammad Alharbi, Nuha Abdullah Althomali, Ibrahim Mohammed Alzimam, Abdullah Ayed Alshammari, Bashair Hamed Alharbi, Amer Alshengeti, Abdulmonem A. Alsaleh, Shayea A. Alqahtani, Ali A. Rabaan
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	MDPI AG 2022-11-01
Rangatū:	Biomedicines
Ngā marau:	tuberculosis drug-resistance Mmpl3 SQ109 clinical studies patent
Urunga tuihono:	https://www.mdpi.com/2227-9059/10/11/2793
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!